699 related articles for article (PubMed ID: 23623245)
41. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.
Husain A; Chung S; Faught E; Isojarvi J; McShea C; Doty P
Epilepsia; 2012 Mar; 53(3):521-8. PubMed ID: 22372628
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
Trinka E; Ben-Menachem E; Kowacs PA; Elger C; Keller B; Löffler K; Rocha JF; Soares-da-Silva P
Epilepsia; 2018 Feb; 59(2):479-491. PubMed ID: 29369348
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.
Banach M; Borowicz KK; Czuczwar SJ
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):639-48. PubMed ID: 25740561
[TBL] [Abstract][Full Text] [Related]
44. Adjunctive lacosamide in clinical practice: sodium blockade with a difference?
Stephen LJ; Kelly K; Parker P; Brodie MJ
Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421
[TBL] [Abstract][Full Text] [Related]
45. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Contin M; Albani F; Riva R; Candela C; Mohamed S; Baruzzi A
Ther Drug Monit; 2013 Dec; 35(6):849-52. PubMed ID: 23942540
[TBL] [Abstract][Full Text] [Related]
46. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial.
Beydoun A; Sachdeo RC; Rosenfeld WE; Krauss GL; Sessler N; Mesenbrink P; Kramer L; D'Souza J
Neurology; 2000 Jun; 54(12):2245-51. PubMed ID: 10881247
[TBL] [Abstract][Full Text] [Related]
47. Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults.
Andermann E; Rosenfeld W; Penovich P; Rogin J; Cendes F; Carreño M; Ramsay RE; Ben-Menachem E; Gama H; Rocha F; Soares-da-Silva P; Tosiello R; Blum D; Grinnell T
Epilepsy Res; 2021 Jan; 169():106478. PubMed ID: 33338829
[TBL] [Abstract][Full Text] [Related]
48. Adverse events, placebo and nocebo effects in placebo-treated paediatric patients with refractory focal epilepsies. Analysis of double-blind studies.
Zaccara G; Giovannelli F; Franco V; Cincotta M; Tramacere L; Verrotti A
Epilepsy Res; 2014 Dec; 108(10):1685-93. PubMed ID: 25288026
[TBL] [Abstract][Full Text] [Related]
49. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.
Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P
Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333
[TBL] [Abstract][Full Text] [Related]
50. The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison.
Martyn-St James M; Glanville J; McCool R; Duffy S; Cooper J; Hugel P; Lane PW
Seizure; 2012 Nov; 21(9):665-78. PubMed ID: 22902288
[TBL] [Abstract][Full Text] [Related]
51. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial.
Halász P; Kälviäinen R; Mazurkiewicz-Beldzińska M; Rosenow F; Doty P; Hebert D; Sullivan T;
Epilepsia; 2009 Mar; 50(3):443-53. PubMed ID: 19183227
[TBL] [Abstract][Full Text] [Related]
52. Clinical utility of eslicarbazepine: current evidence.
Zaccara G; Giovannelli F; Cincotta M; Carelli A; Verrotti A
Drug Des Devel Ther; 2015; 9():781-9. PubMed ID: 25709402
[TBL] [Abstract][Full Text] [Related]
53. Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy.
Baulac M; Byrnes W; Williams P; Borghs S; Webster E; De Backer M; Dedeken P
Acta Neurol Scand; 2017 Apr; 135(4):434-441. PubMed ID: 27714769
[TBL] [Abstract][Full Text] [Related]
54. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
55. The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice.
Johannessen Landmark C; Svendsen T; Dinarevic J; Kufaas RF; Reimers A; Brodtkorb E; Baftiu A; Burns ML; Johannessen SI
Ther Drug Monit; 2016 Aug; 38(4):499-505. PubMed ID: 27414974
[TBL] [Abstract][Full Text] [Related]
56. [Long-term effects of dibenzazepines on metabolic parameters: retrospective comparison of carbamazepine, oxcarbazepine and eslicarbazepine acetate in the real world].
Ley M; Principe A; Rocamora R
Rev Neurol; 2020 Jul; 71(2):54-60. PubMed ID: 32627160
[TBL] [Abstract][Full Text] [Related]
57. Eslicarbazepine acetate: an update on efficacy and safety in epilepsy.
Verrotti A; Loiacono G; Rossi A; Zaccara G
Epilepsy Res; 2014 Jan; 108(1):1-10. PubMed ID: 24225327
[TBL] [Abstract][Full Text] [Related]
58. Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice.
Rocamora R; Peltola J; Assenza G; McMurray R; Villanueva V
Seizure; 2020 Feb; 75():121-128. PubMed ID: 31981862
[TBL] [Abstract][Full Text] [Related]
59. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group.
Glauser TA; Nigro M; Sachdeo R; Pasteris LA; Weinstein S; Abou-Khalil B; Frank LM; Grinspan A; Guarino T; Bettis D; Kerrigan J; Geoffroy G; Mandelbaum D; Jacobs T; Mesenbrink P; Kramer L; D'Souza J
Neurology; 2000 Jun; 54(12):2237-44. PubMed ID: 10881246
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
